A new startup sets course against a constellation of rare diseases with a first shot repurposing the SIRP pathway

Kyle Blankenship

Despite some big advances in recent years, rare disease remains a mostly uncharted wilderness with many patients left underserved. A startup with galactic ambitions now …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

A new startup sets course against a constellation of rare diseases with a first shot repurposing the SIRP pathway

Kyle Blankenship

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

FDA approves first drug to treat ultra-rare lipid storage disease

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA says Ozempic, Wegovy shortage is over

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

A new start­up sets course against a con­stel­la­tion of rare dis­eases with a first shot re­pur­pos­ing the SIRP path­way

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

A new startup sets course against a constellation of rare diseases with a first shot repurposing the SIRP pathway